Corporate
2023.09.26
Lumosa Partner, AMed Co., Informed the Receipt of Market Authorization from Brunei (BDMCA), for Naldebain, an Extended-Release Analgesic Injection
Corporate
2023.07.26
LT3001 Received Formulation Patent from USPTO
Corporate
2023.05.15
Lumosa’s LT1001 Received First European Approval from Ukraine’s SMDC
Corporate
2023.04.19
First subject for LT3001 Phase 2 trial enrolled in China
Corporate
2023.03.20
Lumosa team to attend STAIR XII
Corporate
2023.03.07
Lumosa Therapeutics Announces an Out-License Agreement with Pakistan’s AJM Pharma for LT1001